Relationships Among FVIII, t-PA/PAI-1, and MMP-9 Levels and Intracranial Hemorrhage Complications After Thrombolysis With Alteplase in Patients With Acute Ischemic Stroke: Protocol for a Multicenter Retrospective Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-12

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of the study is to investigate the relationships among FVIII, t-PA/PAI-1, MMP-9 levels, and intracranial hemorrhage after thrombolysis with alteplase using a combined analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Establishment and Validation of a Predictive Model for Hemorrhage

NCT04745052

Stroke, Acute

UNKNOWN

The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients

NCT03571763

Ischemic Stroke

RECRUITING

Neuroinflammatory Response in Patients With ICH and IVH Treated With rtPA

NCT03452722

Hypertensive Intracerebral Hemorrhage Intraventricular Hemorrhage Brain Injuries

COMPLETED

Hemodynamic Changes in Acute Ischaemic Stroke Patients

NCT05195983

Acute Stroke

UNKNOWN

Predictors and Prognostic Factors on the Acute Ischemic Stroke

NCT03122002

Ischemic Stroke

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with acute ischemic stroke treated with alteplase within 4.5 hours after the onset of stroke symptoms will be recruited in this study. All participants will be divided into two groups according to whether intracranial hemorrhage occurred within 3 days after treatment with alteplase for analysis. Differences in FVIII, t-PA/PAI-1, and MMP-9 levels before and after thrombolytic therapy will be examined in both groups. This study will be conducted at Zhujiang Hospital of Southern Medical University, Nanfang Hospital of Southern Medical University, and the First Affiliated Hospital of Jinan University.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental group

The patients who were treated with Ateptidase had intracranial haemorrhage adverse reactions

Ateptidase

Intervention Type DRUG

Treatment of ischemic stroke with Ateptidase

control group

The patients who were treated with Ateptidase did not have intracranial haemorrhage adverse reactions.

Ateptidase

Intervention Type DRUG

Treatment of ischemic stroke with Ateptidase

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ateptidase

Treatment of ischemic stroke with Ateptidase

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of ischemic stroke and within the time window of thrombolysis (Onset of symptoms no more than 4.5 hours )
* 18 y age 85 y•
* Symptoms of neurological deficits caused by cerebral infarction
* Informed consent form to confirm thrombolytic therapy have signed by patients or their family.

Exclusion Criteria

* A history of major head trauma or stroke in the past 3 months
* Suspicious subarachnoid hemorrhage
* Arterial puncture at noncompressible site in the last week
* History of intracranial hemorrhage
* Intracranial neoplasm, arteriovenous malformation, or aneurysm
* Recent intracranial or intraspinal surgery
* Elevated blood pressure (systolic \>185 mm Hg or diastolic \>110 mm Hg)
* Active internal bleeding or Acute bleeding diathesis
* Platelet count \<100×109·L-1
* Heparin received within 48 h resulting in aPTT above the upper limit of normal
* Current use of anticoagulant with INR \>1.7 or PT \>15 s
* Current use of thrombin inhibitors or factor Xa inhibitors
* Abnormal laboratory tests (eg, aPTT, INR, platelet count, ECT, TT, or appropriate factor Xa activity assays)
* Blood glucose concentration \> 2.7 mmol/L
* CT demonstrates multilobar infarction (hypodensity \>1/3 cerebral hemisphere)
* Mild cerebral infarction or rapid improvement of symptoms of cerebral infarction
* Symptoms of neurological impairment after seizures
* Major surgery or severe trauma in the past 2 weeks
* Gastrointestinal or urinary bleeding in the past 3 weeks
* History of myocardial infarction in the past 3 months
* Combine diseases that may affect outcomes,such as Anemia, hemophilia
* History of autoimmune disease or organ transplantation
* Pregnancy or breastfeeding women

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No